Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Fresh from the biologic pipeline-2009.

Literature DB >> 20379168

Fresh from the biologic pipeline-2009.

Cormac Sheridan.

Abstract

Mesh：

Substances：

Year: 2010 PMID： 20379168 DOI： 10.1038/nbt0410-307

Source DB: PubMed Journal: Nat Biotechnol ISSN： 1087-0156 Impact factor: 54.908

× No keyword cloud information.

3 in total

1. 2009 FDA drug approvals.

Authors: Bethan Hughes
Journal: Nat Rev Drug Discov Date: 2010-02 Impact factor: 84.694

2. Golimumab.

Authors: Dimitrios A Pappas; Joan M Bathon; Delphine Hanicq; Uma Yasothan; Peter Kirkpatrick
Journal: Nat Rev Drug Discov Date: 2009-09 Impact factor: 84.694

3. Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study.

Authors: Benjamin M Segal; Cris S Constantinescu; Aparna Raychaudhuri; Lilianne Kim; Rosanne Fidelus-Gort; Lloyd H Kasper
Journal: Lancet Neurol Date: 2008-09 Impact factor: 44.182

3 in total

10 in total

1. Biopharmaceutical benchmarks 2010.

Authors: Gary Walsh
Journal: Nat Biotechnol Date: 2010-09 Impact factor: 54.908

2. Analysis of intact monoclonal antibody IgG1 by electron transfer dissociation Orbitrap FTMS.

Authors: Luca Fornelli; Eugen Damoc; Paul M Thomas; Neil L Kelleher; Konstantin Aizikov; Eduard Denisov; Alexander Makarov; Yury O Tsybin
Journal: Mol Cell Proteomics Date: 2012-09-10 Impact factor: 5.911

3. Conformational characterization of the charge variants of a human IgG1 monoclonal antibody using H/D exchange mass spectrometry.

Authors: Liangjie Tang; Shanmuuga Sundaram; Jingming Zhang; Ping Carlson; Alice Matathia; Babita Parekh; Qinwei Zhou; Ming-Ching Hsieh
Journal: MAbs Date: 2012-12-06 Impact factor: 5.857

Fresh from the biologic pipeline-2009.

1. 2009 FDA drug approvals.

2. Golimumab.

3. Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study.

1. Biopharmaceutical benchmarks 2010.

2. Analysis of intact monoclonal antibody IgG1 by electron transfer dissociation Orbitrap FTMS.

3. Conformational characterization of the charge variants of a human IgG1 monoclonal antibody using H/D exchange mass spectrometry.

Review 4. Stimulation of anti-tumor immunity by photodynamic therapy.

5. Tissue integration of growth factor-eluting layer-by-layer polyelectrolyte multilayer coated implants.

Review 6. Modeling, simulation, and translation framework for the preclinical development of monoclonal antibodies.

7. Systematic single-cell analysis of Pichia pastoris reveals secretory capacity limits productivity.

Review 8. Applicability of predictive toxicology methods for monoclonal antibody therapeutics: status Quo and scope.

9. Enhanced production of recombinant secretory proteins in Pichia pastoris by optimizing Kex2 P1' site.

Review 10. Patterning Biomaterials for the Spatiotemporal Delivery of Bioactive Molecules.